Acceleration of interstitial lung disease induced by raltitrexed
File(s)
Accepted version
Author(s)
Howlett, Sarah
Aul, Raminder
Hill, Mark
Pinato, David J
Type
Journal Article
Abstract
Introduction
Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities.
Case report
We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma.
Management and outcome
Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests.
Discussion
The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed.
Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities.
Case report
We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma.
Management and outcome
Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests.
Discussion
The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed.
Date Issued
2019-11-19
Date Acceptance
2019-10-17
Citation
Journal of Oncology Pharmacy Practice, 2019, 26 (5), pp.1241-1243
ISSN
1078-1552
Publisher
SAGE Publications
Start Page
1241
End Page
1243
Journal / Book Title
Journal of Oncology Pharmacy Practice
Volume
26
Issue
5
Copyright Statement
© The Author(s) 2019. The final, definitive version of this paper has been published in Howlett, S., Aul, R., Hill, M., & Pinato, D. J. (2019). Acceleration of interstitial lung disease induced by raltitrexed. Journal of Oncology Pharmacy Practice by Sage Publications Ltd. All rights reserved. It is available at: https://doi.org/10.1177/1078155219887213
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000498340300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Pharmacology & Pharmacy
Raltitrexed
pulmonary toxicity
colorectal carcinoma
Publication Status
Published
Article Number
UNSP 1078155219887213
Date Publish Online
2019-11-19